Redx to present new scientific data at AACR 2017

3 March 2017

Redx Pharma Plc is pleased to announce that it will present two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in Washington D.C., USA.

Session Date & Time April 5, 2017, 8:00 AM -12:00 PM Eastern Time
Session Title Enzymes and Hormones and Metabolism in Tumor Immunity
Presentation Title Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors
Session Location Section 24
Abstract # 5581 / 13
First author Thomas Pesnot
Abstract online http://www.abstractsonline.com/pp8/#!/4292/presentation/6237
Session Date & Time April 5, 2017, 8:00 AM -12:00 PM Eastern Time
Session Title Oncogenes and Tumor Suppressors as Therapeutic Targets
Presentation Title Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS tumors
Session Location Section 6
Abstract # 5160 / 3
First author Helen Mason
Abstract online http://www.abstractsonline.com/pp8/#!/4292/presentation/4116

Dr Neil Murray, CEO of Redx, said: We're delighted to present new scientific data on two of our pre-clinical programs at the AACR meeting in April. As we are moving closer to the clinic with our most advanced programs, the Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005, we continue to look for novel opportunities in several therapeutic classes in oncology and immunology.